Third Rock’s Rapport reveals upsized $154M IPO

Just a few days after Rapport Therapeutics revealed plans for a $122 million IPO, the epilepsy biotech has unveiled an upsized $154 million offering.

The Third Rock company’s IPO consists of 8 million shares, with a previous range set for $16 to $18 per share. Now, the biotech has debuted at $17 per share, an offering expected to close June 10. Shares are listed under the symbol RAPP.